Literature DB >> 10807940

Stereoselective sulfoxidation of sulindac sulfide by flavin-containing monooxygenases. Comparison of human liver and kidney microsomes and mammalian enzymes.

M A Hamman1, B D Haehner-Daniels, S A Wrighton, A E Rettie, S D Hall.   

Abstract

The stereoselective sulfoxidation of the pharmacologically active metabolite of sulindac, sulindac sulfide, was characterized in human liver, kidney, and cDNA-expressed enzymes. Kinetic parameter estimates (pH = 7.4) for sulindac sulfoxide formation in human liver microsomes (N = 4) for R- and S-sulindac sulfoxide were V(max) = 1.5 +/- 0.50 nmol/min/mg, K(m) = 15 +/- 5.1 microM; and V(max) = 1.1 +/- 0.36 nmol/min/mg, K(m) = 16 +/- 6.1 microM, respectively. Kidney microsomes (N = 3) produced parameter estimates (pH = 7.4) of V(max) = 0.9 +/- 0.29 nmol/min/mg, K(m) = 15 +/- 2.9 microM; V(max) = 0.5 +/- 0.21 nmol/min/mg, K(m) = 22 +/- 1.9 microM for R- and S-sulindac sulfoxide, respectively. In human liver and flavin-containing monooxygenase 3 (FMO3) the V(max) for R-sulindac sulfoxide increased 60-70% at pH = 8.5, but for S-sulindac sulfoxide was unchanged. In fourteen liver microsomal preparations, significant correlations occurred between R-sulindac sulfoxide formation and either immunoquantified FMO or nicotine N-oxidation (r = 0.88 and 0.83; P < 0.01). The R- and S-sulindac sulfoxide formation rate also correlated significantly (r = 0.85 and 0.75; P < 0.01) with immunoquantified FMO in thirteen kidney microsomal samples. Mild heat deactivation of microsomes reduced activity by 30-60%, and a loss in stereoselectivity was observed. Methimazole was a potent and nonstereoselective inhibitor of sulfoxidation in liver and kidney microsomes. n-Octylamine and membrane solubilization with lubrol were potent and selective inhibitors of S-sulindac sulfoxide formation. cDNA-expressed CYPs failed to appreciably sulfoxidate sulindac sulfide, and CYP inhibitors were ineffective in suppressing catalytic activity. Purified mini-pig liver FMO1, rabbit lung FMO2, and human cDNA-expressed FMO3 efficiently oxidized sulindac sulfide with a high degree of stereoselectivity towards the R-isomer, but FMO5 lacked catalytic activity. The biotransformation of the sulfide to the sulfoxide is catalyzed predominately by FMOs and may prove to be useful in characterizing FMO activity.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10807940     DOI: 10.1016/s0006-2952(00)00301-4

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  14 in total

1.  The metabolism and pharmacokinetics of phospho-sulindac (OXT-328) and the effect of difluoromethylornithine.

Authors:  G Xie; T Nie; G G Mackenzie; Y Sun; L Huang; N Ouyang; N Alston; C Zhu; O T Murray; P P Constantinides; L Kopelovich; B Rigas
Journal:  Br J Pharmacol       Date:  2012-04       Impact factor: 8.739

2.  Synthesis of optically pure S-sulfoxide by Escherichia coli transformant cells coexpressing the P450 monooxygenase and glucose dehydrogenase genes.

Authors:  Jian-Dong Zhang; Ai-Tao Li; Hui-Lei Yu; Tadayuki Imanaka; Jian-He Xu
Journal:  J Ind Microbiol Biotechnol       Date:  2010-08-19       Impact factor: 3.346

3.  Sulindac and its metabolites inhibit multiple transport proteins in rat and human hepatocytes.

Authors:  Jin Kyung Lee; Mary F Paine; Kim L R Brouwer
Journal:  J Pharmacol Exp Ther       Date:  2010-04-29       Impact factor: 4.030

4.  Flavin-containing monooxygenase-3: induction by 3-methylcholanthrene and complex regulation by xenobiotic chemicals in hepatoma cells and mouse liver.

Authors:  Trine Celius; Andrea Pansoy; Jason Matthews; Allan B Okey; Marilyn C Henderson; Sharon K Krueger; David E Williams
Journal:  Toxicol Appl Pharmacol       Date:  2010-06-04       Impact factor: 4.219

5.  Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.

Authors:  Irfan M Hisamuddin; Mohammad A Wehbi; Brian Schmotzer; Kirk A Easley; Linda M Hylind; Francis M Giardiello; Vincent W Yang
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-10       Impact factor: 4.254

Review 6.  Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolism.

Authors:  Sharon K Krueger; David E Williams
Journal:  Pharmacol Ther       Date:  2005-06       Impact factor: 12.310

7.  Studies on the metabolism and biological activity of the epimers of sulindac.

Authors:  David Brunell; Daphna Sagher; Shailaja Kesaraju; Nathan Brot; Herbert Weissbach
Journal:  Drug Metab Dispos       Date:  2011-03-07       Impact factor: 3.922

Review 8.  Pharmacogenetics and diseases of the colon.

Authors:  Irfan M Hisamuddin; Mohammad A Wehbi; Vincent W Yang
Journal:  Curr Opin Gastroenterol       Date:  2007-01       Impact factor: 3.287

9.  Novel variants of the human flavin-containing monooxygenase 3 (FMO3) gene associated with trimethylaminuria.

Authors:  Meike S Motika; Jun Zhang; Xueying Zheng; Kiersten Riedler; John R Cashman
Journal:  Mol Genet Metab       Date:  2009-02-27       Impact factor: 4.797

Review 10.  Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives.

Authors:  Irfan M Hisamuddin; Vincent W Yang
Journal:  Pharmacogenomics       Date:  2007-06       Impact factor: 2.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.